Cargando…

Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system

INTRODUCTION: Pediatric severe sepsis (PSS) continues to be a major health problem. Extracorporeal therapies (ETs), defined as extracorporeal membrane oxygenation (ECMO) and RRenal replacement therapyenal replacement therapy (RRT), are becoming more available for utilization in a variety of health c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruth, Amanda, McCracken, Courtney E., Fortenberry, James D., Hebbar, Kiran B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640405/
https://www.ncbi.nlm.nih.gov/pubmed/26552921
http://dx.doi.org/10.1186/s13054-015-1105-4
_version_ 1782400069087002624
author Ruth, Amanda
McCracken, Courtney E.
Fortenberry, James D.
Hebbar, Kiran B.
author_facet Ruth, Amanda
McCracken, Courtney E.
Fortenberry, James D.
Hebbar, Kiran B.
author_sort Ruth, Amanda
collection PubMed
description INTRODUCTION: Pediatric severe sepsis (PSS) continues to be a major health problem. Extracorporeal therapies (ETs), defined as extracorporeal membrane oxygenation (ECMO) and RRenal replacement therapyenal replacement therapy (RRT), are becoming more available for utilization in a variety of health conditions. We aim to describe (1) rates of utilization of ET in PSS, (2) outcomes for PSS patients receiving ET, and (3) epidemiologic characteristics of patients receiving ET. METHODS: We conducted a retrospective review of a prospectively collected database. Data from the Pediatric Health Information System (PHIS) database collected by the Children’s Hospital Association (CHA) from 2004–2012 from 43 US children’s hospitals’ pediatric intensive care units (PICUs) were used. Patients with PSS were defined by (1) International Classification of Diseases, 9th Revision (ICD-9) codes reflecting severe sepsis and septic shock and (2) ICD-9 codes of infection and organ dysfunction as defined by updated Angus criteria. Among the patients with PSS, those with a PHIS flag of ECMO or RRT were identified further as our main cohort. RESULTS: From 2004 to 2012, 636,842 patients were identified from 43 hospitals, and PSS prevalence was 7.7 % (49,153 patients). Nine point eight percent (4795 patients) received at least one form of ET, and the associated mortality rate was 39 %. Mortality rates were 47.8 % for those who received ECMO, 32.3 % in RRT, and 58.0 % in RRT + ECMO. Underlying co-morbidities were found in 3745 patients (78.1 %) who received ET (81 % for ECMO, 77.9 % in RRT, and 71.2 % in those who received both). There was a statistically significant increase in ECMO utilization in patients with at least three organ dysfunctions from 2004 to 2012 (6.9 % versus 10.3 %, P < 0.001) while RRT use declined (24.5 % versus 13.2 %, P < 0.001). After 2009, there was a significant increase in ECMO utilization (3.6 % in 2004–2008 versus 4.0 % in 2009–2012, P = 0.004). ECMO and RRT were used simultaneously in only 500 patients with PSS (1 %). CONCLUSIONS: ETs were used in a significant portion of PSS patients with multiple organ dysfunction syndrome (MODS) during this time period. Mortality was significant and increased with increasing organ failure. ECMO use in PSS patients with MODS increased from 2004 to 2012. Further evaluation of ET use in PSS is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-1105-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4640405
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46404052015-11-11 Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system Ruth, Amanda McCracken, Courtney E. Fortenberry, James D. Hebbar, Kiran B. Crit Care Research INTRODUCTION: Pediatric severe sepsis (PSS) continues to be a major health problem. Extracorporeal therapies (ETs), defined as extracorporeal membrane oxygenation (ECMO) and RRenal replacement therapyenal replacement therapy (RRT), are becoming more available for utilization in a variety of health conditions. We aim to describe (1) rates of utilization of ET in PSS, (2) outcomes for PSS patients receiving ET, and (3) epidemiologic characteristics of patients receiving ET. METHODS: We conducted a retrospective review of a prospectively collected database. Data from the Pediatric Health Information System (PHIS) database collected by the Children’s Hospital Association (CHA) from 2004–2012 from 43 US children’s hospitals’ pediatric intensive care units (PICUs) were used. Patients with PSS were defined by (1) International Classification of Diseases, 9th Revision (ICD-9) codes reflecting severe sepsis and septic shock and (2) ICD-9 codes of infection and organ dysfunction as defined by updated Angus criteria. Among the patients with PSS, those with a PHIS flag of ECMO or RRT were identified further as our main cohort. RESULTS: From 2004 to 2012, 636,842 patients were identified from 43 hospitals, and PSS prevalence was 7.7 % (49,153 patients). Nine point eight percent (4795 patients) received at least one form of ET, and the associated mortality rate was 39 %. Mortality rates were 47.8 % for those who received ECMO, 32.3 % in RRT, and 58.0 % in RRT + ECMO. Underlying co-morbidities were found in 3745 patients (78.1 %) who received ET (81 % for ECMO, 77.9 % in RRT, and 71.2 % in those who received both). There was a statistically significant increase in ECMO utilization in patients with at least three organ dysfunctions from 2004 to 2012 (6.9 % versus 10.3 %, P < 0.001) while RRT use declined (24.5 % versus 13.2 %, P < 0.001). After 2009, there was a significant increase in ECMO utilization (3.6 % in 2004–2008 versus 4.0 % in 2009–2012, P = 0.004). ECMO and RRT were used simultaneously in only 500 patients with PSS (1 %). CONCLUSIONS: ETs were used in a significant portion of PSS patients with multiple organ dysfunction syndrome (MODS) during this time period. Mortality was significant and increased with increasing organ failure. ECMO use in PSS patients with MODS increased from 2004 to 2012. Further evaluation of ET use in PSS is warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-015-1105-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-10 2015 /pmc/articles/PMC4640405/ /pubmed/26552921 http://dx.doi.org/10.1186/s13054-015-1105-4 Text en © Ruth et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ruth, Amanda
McCracken, Courtney E.
Fortenberry, James D.
Hebbar, Kiran B.
Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system
title Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system
title_full Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system
title_fullStr Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system
title_full_unstemmed Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system
title_short Extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system
title_sort extracorporeal therapies in pediatric severe sepsis: findings from the pediatric health-care information system
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640405/
https://www.ncbi.nlm.nih.gov/pubmed/26552921
http://dx.doi.org/10.1186/s13054-015-1105-4
work_keys_str_mv AT ruthamanda extracorporealtherapiesinpediatricseveresepsisfindingsfromthepediatrichealthcareinformationsystem
AT mccrackencourtneye extracorporealtherapiesinpediatricseveresepsisfindingsfromthepediatrichealthcareinformationsystem
AT fortenberryjamesd extracorporealtherapiesinpediatricseveresepsisfindingsfromthepediatrichealthcareinformationsystem
AT hebbarkiranb extracorporealtherapiesinpediatricseveresepsisfindingsfromthepediatrichealthcareinformationsystem